Anavex Life Sciences

Anavex Life Sciences has met Nasdaq requirements after submitting the outstanding Form 10‑Q reports for the second and third quarters of 2026. Nasdaq confirmed the company now complies with Rule 5250(c)(1) and will continue to trade on the Nasdaq Global Select Market under the ticker symbol AVXL. Previously, Anavex had been delinquent in timely filing its quarterly reports. » More on de.investing.com

Anavex has filed final proxy materials for the September 24 annual meeting and is urging shareholders to support its six nominees for the board of directors after entering a proxy fight with PVG Asset Management. Shareholders of record as of July 31, 2026, are eligible to vote; if elected, half of the board would have been replaced since the start of the year. The biopharma company named Dr. Terrie Kellmeyer as interim CEO, filed an IND application for an Alzheimer’s treatment, and is conducting two clinical pharmacology studies. In May Anavex received a Nasdaq deficiency notice for a late 10‑Q filing and has submitted a compliance plan; PVG and Patrick Adams together hold 0.35% of the outstanding shares. » More on de.investing.com

Anavex Life Sciences missed timely filing of the quarterly report (Form 10-Q) for the quarter ended March 31, 2026, thereby violating NASDAQ listing rule 5250(c)(1). NASDAQ set a deadline of July 20, 2026 to submit a plan to regain compliance. The stock last fell 6.9% to $2.71 and trades near its 52-week low; Anavex is working to complete and file the report. The notice has no immediate effect on the listing of the common stock. » More on de.investing.com